Assess safety, tolerability and PK of AZD3199 in Japanese

Study identifier:D0570C00005

ClinicalTrials.gov identifier:N/A

EudraCT identifier:2008-004448-35

CTIS identifier:N/A

Study Complete

Official Title

A phase I, randomised, double-blind, placebo-controlled, parallel-group, single-centre study to investigate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of AZD3199 given once daily as inhaled formulation via Turbuhaler to Japanese healthy men

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD3199 Turbuhaler®, Placebo Turbuhaler®

Sex

Male

Actual Enrollment

27

Study type

Interventional

Age

20 Years - 45 Years

Date

Study Start Date: 01 Oct 2008
Primary Completion Date: -
Study Completion Date: 01 Feb 2009

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria